Hemostemix Announces First Patient Treated in Phase II Clinical TrialMay 3, 2018
CALGARY, Alberta, May 03, 2018 — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has treated its first patient under its continuing Phase II Clinical Trial for critical limb ischemia (“CLI”). The first patient was treated at the Vancouver Coastal Health Research Institute (“VCHRI”), a world leader in translational health research for new therapies, led by the principal investigator, Dr. York N. Hsiang, MB ChB MHSc FRCSC.
As previously announced, the VCHRI is the Company’s first Canadian trial site that is actively onboarding patients for the
continuing trial. The Company has approximately 14 additional clinical trial sites located in Canada and the United States that are in various stages of the on-boarding process including 5 sites that have approved the Company’s clinical trial agreement pending final review board or budget approvals.
The ongoing Phase II clinical trial investigates the safety and efficacy of the Company’s lead product, ACP-01. The
Company’s patented process results in producing specific stem cells that have the ability to support the generation of new
blood vessels to combat the life-threatening complications of CLI. The stem cells are raised and expanded from the patient’s blood and then re-injected into the diseased tissue. The results of the current clinical trial will determine whether the curative effects seen in Phase I trials of ACP-01 will be equally strong in a larger and more varied patient group.
“We are thrilled to be participating in the clinical trial of this potentially game-changing therapy for patients with CLI. This trial is an important step forward in technology for treating vascular diseases such as CLI.” said Dr. Hsiang.
“This first patient treatment is a critical milestone for Hemostemix as we continue to advance ACP-01 as a potentially
revolutionary treatment for CLI and other diseases,” states Kyle Makofka, Chief Executive Officer and President of
Hemostemix. “The millions of patients who suffer from CLI have limited treatment options outside of amputation, so the
benefits of ACP-01 therapy could be a vital treatment option resulting in bettering lives.”
The Company is also pleased to announce the appointment of Kristin Gulka, CPA, CA as the Company’s Chief Financial
Officer effective May 1, 2018, subject to regulatory approval.
Ms. Gulka has over 10 years of financial, accounting and management experience for public and private companies. For the past 7 years, she worked in a number of roles, including controller and corporate controller, within the finance department at Ferus, a Calgary-based energy service and liquid natural gas company with operations throughout North America. Prior thereto, she was interim controller at SemBioSys Genetics Inc., a biotechnology company conducting phase I and II clinical trials. Kristin was named to the National Honour Roll when she completed her Uniform Final Exam (now known as the Common Final Examination) and went on to achieve her Chartered Professional Accountant (CA) designation. She also obtained a Bachelor of Commerce (Accounting) degree from the University of Calgary.
The Company also announces the departure of David Berman from the position of Chief Financial Officer, but he will remain with the Company on a temporary consulting basis. We thank David for his contributions to the Company and wish him well with his future endeavors.
“We are delighted to have Kristin Gulka join Hemostemix in the capacity of CFO. Her extensive experience in accounting and strong financial oversight make her a welcome member of the executive team, as we move forward with Hemostemix’s global initiatives,” said Kyle Makofka.
To Download the Full Press Release Click Here.
View All News & Media